MedTrace Logo

Statin Therapy to Reduce Progression in Women With Platinum Sensitive Ovarian Cancer

NCT04457089 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2026-02-04

No results posted yet for this study

Summary

This is a single arm pilot trial to evaluate the feasibility of using a simvastatin intervention, and to evaluate its effects on cancer progression, among 20 patients with platinum-sensitive ovarian cancer, treated with carboplatin and liposomal doxorubicin at Cedars-Sinai Medical Center.

Conditions

  • Recurrent Ovarian Cancer
  • Platinum-sensitive Ovarian Cancer

Interventions

DRUG

Simvastatin 40mg

Simvastatin 40mg by mouth nightly for approximately 6 months during treatment with carboplatin and liposomal doxorubicin

Sponsors & Collaborators

  • Marc Goodman

    lead OTHER

Principal Investigators

  • Bobbie Jo Rimel, MD · Cedars-Sinai Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-25
Primary Completion
2024-11-01
Completion
2025-05-12
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04457089 on ClinicalTrials.gov